Cancer peptide vaccines, comprised of neoepitopes presented by MHC-I, are a promising approach, as they elicit tumor-targeted, cell-mediated responses by mobilizing tumor-specific CD8+ T cells to eliminate tumor cells [3]. The gene discussed is CD8A; the disease is neoplasm.